The shorter OS may be partly due to the exclusion of IDH-mutant astrocytomas with relatively better survival and the introduction of mol-GBMs that are more infiltrative and less responsive to TMZ chemotherapy. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).